North America Hepatitis Delta Virus Hdv Infection Market
市场规模（十亿美元）
CAGR :
% 
USD
7.13 Million
USD
10.06 Million
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 7.13 Million |
 Market Size (Forecast Year) |
USD 10.06 Million |
 CAGR |
% |
| Major Markets Players |
|
北美丁型肝炎病毒 (HDV)感染市場細分，按類型（急性丁型肝炎和慢性丁型肝炎）、治療（手術（肝臟移植）和藥物治療）、藥物類型（品牌藥和仿製藥）、給藥途徑（口服和腸外給藥）、年齡組（成人、老年人和兒童）、性別（女性和男性）、傳播方式（受污染的針頭、接觸受感染的血液、血液和血漿製品輸血等）、最終用戶（醫院、專科診所、家庭護理機構、研究機構和學術中心、門診手術中心等）、分銷渠道（直接投標、零售等） - 產業趨勢和預測至 2032 年
北美丁型肝炎病毒（HDV）感染市場規模
- 2024 年北美丁型肝炎病毒 (HDV) 感染市場規模價值713 萬美元 ，預計 到 2032 年將達到 1,006 萬美元，預測期內 複合年增長率為 4.60%。
- 市場成長主要得益於乙肝病毒（HBV）合併感染的日益流行以及人們對肝臟健康的認識不斷提高，尤其是在北美地區乙肝病毒流行的國家。政府主導的公共衛生措施和診斷能力的提升使得丁肝病毒（HDV）的早期發現和治療成為可能，加速了市場擴張。
- 此外，抗病毒研究投入的不斷增長，以及包括RNA標靶藥物和新型乾擾素療法在內的先進療法的上市，正使丁型肝炎病毒（HDV）標靶治療成為更廣泛肝病學領域中關鍵的細分領域。這些因素的共同作用正在加速北美丁型肝炎病毒（HDV）感染解決方案的普及，從而顯著推動該地區新興和已開發醫療市場的產業成長。
北美丁型肝炎病毒（HDV）感染市場分析
- 北美丁型肝炎病毒 (HDV) 感染市場正在經歷顯著增長，這得益於該地區已開發國家意識的提高、診斷能力的提高以及先進醫療服務的普及。
- 肝臟相關疾病負擔的加重、醫療支出的增加以及政府主導的肝炎消除計劃是推動北美市場擴張的主要因素
- 美國在北美丁型肝炎病毒 (HDV) 感染市場佔據主導地位，2024 年的收入份額最大，為 46.84%，這得益於其強大的醫療基礎設施、先進的診斷技術以及聯邦和州級廣泛實施的肝炎控制計劃
- 預計墨西哥將成為北美丁型肝炎病毒 (HDV) 感染市場成長最快的國家，預測期內複合年增長率為 6.9%，這得益於醫療保健意識的提高、公共衛生基礎設施投資的增加以及與國際衛生機構合作擴大肝炎篩檢和治療管道的努力
- 腸外給藥途徑領域在北美丁型肝炎病毒 (HDV) 感染市場佔據主導地位，2024 年的份額為 66.5%，這得益於注射用聚乙二醇幹擾素作為標準治療的廣泛使用，確保了有效的病毒抑制並與整個地區既定的臨床方案保持一致
報告範圍和北美丁型肝炎病毒 (HDV) 感染市場細分
|
屬性 |
北美丁型肝炎病毒 (HDV) 感染關鍵市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋國家 |
北美洲
|
|
主要市場參與者 |
|
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括深入的專家分析、定價分析、品牌份額分析、消費者調查、人口統計分析、供應鏈分析、價值鏈分析、原材料/消耗品概述、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
北美丁型肝炎病毒（HDV）感染市場趨勢
“越來越多地採用先進的診斷和監測技術”
- 北美丁型肝炎病毒 (HDV) 感染市場的一個重要且加速的趨勢是先進診斷平台和數位健康生態系統的深度整合，旨在改善早期檢測、疾病監測和患者依從性
- 例如，領先的診斷製造商正在推出針對丁型肝炎病毒（HDV）的檢測試劑盒和基於即時PCR的解決方案，以便更快、更準確地檢測合併感染乙肝病毒的患者中的丁型肝炎病毒。這些進步正被中國、印度和日本等國家的醫院和診斷中心越來越多地採用。
- 數位健康平台也使疾病追蹤、病患教育和後續護理更有效率。一些行動健康應用程式現在可以幫助醫護人員監測肝功能、治療順從性和患者報告的療效，從而促進更個人化的丁肝病毒 (HDV) 護理路徑。
- 診斷工具與電子病歷（EMR）和國家肝炎登記冊的無縫整合進一步增強了監測能力，使政策制定者能夠有效地分配資源並瞄準高風險人群
- 這種更聰明、數據驅動、互聯互通的疾病管理解決方案趨勢正在從根本上重塑人們對丁型肝炎（HDV）護理和治療的期望。因此，北美地區的公司和醫療保健系統正在投資可擴展的診斷創新和遠距醫療平台，以擴大其覆蓋範圍。
- 隨著利害關係人越來越重視早期介入、高效的患者追蹤和全面的傳染病管理，公共和私人醫療保健領域對可靠、快速和整合的診斷工具的需求正在迅速增長
北美丁型肝炎病毒（HDV）感染市場動態
司機
“疾病負擔加重和未滿足的醫療需求導致需求不斷增長”
- 由於乙肝和丁肝合併感染的流行，北美丁型肝炎病毒 (HDV) 感染市場正在加速成長，這導致該地區對有效診斷和治療的需求不斷增長
- 例如，中國、印度和巴基斯坦等國家報告的乙肝病毒帶菌率較高，增加了丁肝病毒重疊感染的風險。這促使地區政府和衛生機構優先進行肝炎篩檢和治療項目，從而推動了丁肝病毒市場的發展。
- 此外，醫療保健支出的增加、診斷檢測機會的擴大以及病毒性肝炎宣傳活動的加強，都極大地促進了該地區對丁型肝炎治療解決方案的需求
- 抗病毒療法和肝病管理的進步，以及全球製藥公司和當地醫療保健提供者之間的合作，預計將加速亞太地區丁型肝炎藥物的開發和分銷
- 布韋肽和其他進入抑制劑等新治療方法的出現以及臨床試驗參與度的提高，正在加強該地區的治療前景
克制/挑戰
“獲得專業診斷的機會有限且成本限制”
- 儘管需求不斷增長，但由於丁型肝炎病毒專用檢測試劑盒供應有限以及需要先進的實驗室基礎設施，北美一些國家在診斷和治療丁型肝炎方面仍面臨挑戰
- 由於醫護人員和病患意識不足而導致的診斷延遲仍然是一個主要障礙，尤其是在農村或資源匱乏的地區
- 此外，丁型肝炎治療藥物（如新興生物製劑或進入抑制劑）價格昂貴，限制了很大一部分人口的負擔能力
- 一些亞太國家的報銷限制和缺乏有針對性的國家策略也阻礙了人們獲得標準化的丁型肝炎治療途徑
- 為了克服這些挑戰，增加對肝病篩檢計畫的資金投入、開發負擔得起的生物相似藥以及加強醫療保健基礎設施對於充分發揮北美 HDV 感染市場的潛力至關重要
北美丁型肝炎病毒 (HDV) 感染市場範圍
市場根據類型、治療、藥物類型、給藥途徑、年齡層、性別、傳播、最終用戶和分銷管道進行細分。
• 依類型
根據感染類型，北美丁型肝炎病毒 (HDV) 感染市場可分為急性丁型肝炎和慢性丁型肝炎。慢性丁型肝炎在 2024 年佔據了最大的市場收入份額，達 71.3%，這主要得益於長期感染負擔加重、治療時間延長以及肝硬化和肝細胞癌等肝臟併發症風險增加。由於B肝病毒帶因者檢測水準的提高，慢性丁型肝炎病例的診斷率也隨之提高。
預計急性丁型肝炎領域將在 2025 年至 2032 年間實現 6.7% 的最快成長率，這得益於更好的疾病監測、公共衛生舉措和改進的早期篩檢技術。
• 依治療
根據治療方案，北美丁型肝炎病毒 (HDV) 感染市場細分為手術（肝臟移植）和藥物治療。藥物治療佔據市場主導地位，2024 年收入份額最高，達 88.6%，這主要得益於抗病毒藥物和聚乙二醇幹擾素療法作為一線治療方案的廣泛應用。針對 HDV 特異性病毒機制的研發投入不斷增加，進一步推動了該領域的發展。
預計從 2025 年到 2032 年，手術（肝臟移植）部分將以 5.1% 的複合年增長率最快增長，主要用於藥物治療不再有效的終末期肝衰竭病例。
• 依藥物類型
根據藥物類型，市場細分為品牌藥和仿製藥。 2024年，品牌藥市場收入份額最高，達到63.8%，這得益於諸如布洛韋肽之類的專利療法，這些療法療效顯著，且在三級醫療中心擁有專業的處方模式。
預計仿製藥領域在 2025 年至 2032 年間將實現 7.4% 的最快複合年增長率，這得益於藥物價格可承受性、本地製造的增加以及被納入發展中國家的國家藥品清單。
•依給藥途徑
根據給藥途徑，市場分為口服和腸外給藥。腸外給藥領域在2024年佔據了最大的市場收入份額，達到66.5%，這得益於注射聚乙二醇幹擾素在丁型肝炎（HDV）治療中的標準應用。
隨著臨床試驗中出現有前景的口服抗病毒藥物，以及對非侵入性、患者依從性療法的需求不斷增長，預計口服藥物領域在 2025 年至 2032 年期間的複合年增長率將達到 8.3%，達到最快水平。
• 依年齡組
根據年齡組，市場細分為成人、老年人和兒童。 2024年，成人市場佔據主導地位，市佔率達61.9%，歸因於工作年齡人口和中年人中乙肝病毒（HBV）和丁肝病毒（HDV）合併感染的盛行率較高。
由於老齡人口患肝臟併發症的風險更高且需要更頻繁地接受醫療保健，預計老年人醫療領域在 2025 年至 2032 年期間的複合年增長率將達到 7.1%。
• 按性別
根據性別，市場分為男性和女性。 2024年，男性佔了最大的市場份額，為58.2%，這反映了男性因行為風險因素導致的發病率較高，且B型肝炎（HBV）盛行率較高。
在預測期內，女性市場預計將以 6.5% 的最快複合年增長率增長，這得益於人們認識的提高、孕產婦保健計劃的改善以及生殖健康服務中以性別為重點的篩檢。
• 透過傳輸
根據傳播途徑，北美市場細分為污染針頭、接觸受感染血液、輸血和血漿製品等。由於不安全的注射操作以及部分地區靜脈注射毒品使用量的增加，污染針頭在2024年佔據了最大的市場份額，達到38.6%。
預計血液和血漿製品輸血領域在 2025 年至 2032 年間將實現 7.9% 的最快複合年增長率，這得益於檢測準確性的提高以及一些醫療機構篩檢協議的差距。
• 按最終用戶
根據最終用戶，市場細分為醫院、專科診所、家庭護理機構、研究機構和學術中心、門診手術中心等。醫院細分市場佔據主導地位，2024年的收入份額為47.4%，並由綜合診斷、住院治療和移植基礎設施提供支援。
預計專科診所領域在 2025 年至 2032 年期間的複合年增長率將達到 7.6%，這得益於門診肝臟護理需求的不斷增長、以 HDV 為重點的治療的可用性以及城市擴張。
• 按分銷管道
根據分銷管道，市場細分為直接招標、零售和其他。由於政府採購、醫院用品以及與公共衛生機構合作進行肝炎項目，直接招標市場在2024年佔據了54.3%的最高市場份額。
預計零售部門將以 7.8% 的最快複合年增長率增長，這得益於非處方藥供應的增加以及透過電子藥局和私人診所擴大分銷。
北美丁型肝炎病毒（HDV）感染市場區域分析
- 受公共衛生意識增強、診斷能力增強以及整個地區醫療服務覆蓋範圍擴大的推動，北美丁型肝炎病毒 (HDV) 感染市場在 2025 年至 2032 年預測期內預計將以 30.70% 的最快複合年增長率增長
- 肝臟相關疾病負擔的不斷加重、政府主導的肝炎消除計劃以及醫療保健資金的增加，大大加速了 HDV 診斷和治療解決方案的採用
- 此外，各地區努力將B型肝炎和丁肝篩檢方案納入公共衛生框架，同時改善治療途徑和國際合作，有助於持續擴大市場。
美國丁型肝炎病毒（HDV）感染市場洞察
美國丁型肝炎病毒 (HDV) 感染市場在北美市場佔據主導地位，2024 年其收入份額最高，達到 46.84%，這得益於乙肝的高發病率、強有力的公共衛生舉措以及先進的診斷和治療基礎設施。旨在消除病毒性肝炎的聯邦和州級項目，加上與領先研究機構的合作，正在持續加強全國範圍內丁型肝炎病例的早期發現和有效管理。
加拿大丁型肝炎病毒（HDV）感染市場洞察
加拿大丁型肝炎病毒 (HDV) 感染市場正穩步成長，這得益於其全民健保系統、積極的疾病意識運動以及針對乙型肝炎和丁型肝炎的國家策略。政府支持的篩檢計劃、專科護理的可及性以及對服務不足社區的更多關注正在推動全國範圍內 HDV 診斷和治療的改善。
墨西哥丁型肝炎病毒（HDV）感染市場洞察
預計墨西哥丁型肝炎病毒 (HDV) 感染市場在預測期內將以 6.9% 的複合年增長率位居北美丁型肝炎病毒 (HDV) 感染市場之首，這得益於公共衛生投資的不斷增加、病毒性肝炎意識的不斷提升以及診斷服務可及性的不斷增強。由國際機構支持的國家肝炎計畫正在加強篩檢網絡，並改善抗病毒治療的可及性，尤其是在農村和高危險群中。
北美丁型肝炎病毒（HDV）感染市場份額
北美丁型肝炎病毒 (HDV) 感染產業主要由知名公司主導，包括：
- 吉利德科學公司（美國）
- 基因泰克公司（美國）
- Alnylam Pharmaceuticals, Inc.（美國）
- Assembly Biosciences, Inc.（美國）
- Eiger BioPharmaceuticals（美國）
- GlobeImmune Inc.（美國）
- 華匯健康有限公司 (中國)
- 強生服務公司（美國）
- 藥華醫藥股份有限公司（台灣）
- Replicor（加拿大）
- Vir Biotechnology, Inc.（美國）
北美丁型肝炎病毒（HDV）感染市場的最新發展
- 2024年9月，吉利德科學公司與Genesis Therapeutics達成策略合作，利用先進的AI驅動藥物發現技術探索開發新型療法。此次合作旨在加速創新療法的研發，增強吉利德的研發管線，並鞏固其在競爭激烈的生物製藥產業中的地位。
- 2024年3月，吉利德科學公司完成對CymaBay Therapeutics的收購，獲得了針對肝病和罕見疾病的創新療法。此次收購擴大了吉利德的研發組合，並增強了其產品線，並增強了其滿足未滿足醫療需求的能力。收購CymaBay為吉利德帶來了有前景的候選新藥以及肝病和罕見疾病領域的專業知識，增強了其研發能力，並拓展了治療產品線。
- 2024年3月，吉利德科學公司與Merus宣布合作，共同研發以抗體為基礎的新型三特異性T細胞銜接劑，旨在增強癌症免疫療法。此次合作將吉利德的專業知識與Merus的創新技術結合，共同開發先進的癌症療法。
- 2024年3月，Alnylam Pharmaceuticals 發起了“家族健康史之旅”，旨在推動關於遺傳性澱粉樣變性 (hATTR) 澱粉樣變性的討論。系譜學家 Bernice Bennett 走遍全國，強調家族健康史對早期診斷的重要性。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
4.3 NORTH AMERICA CLINICAL TRIAL MARKET FOR NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
4.4 DISTRIBUTION OF PRODUCTS BY PHASE
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING PREVALENCE OF HEPATITIS
6.1.2 INCREASE IN HEALTHCARE EXPENDITURE
6.1.3 ONGOING RESEARCH AND DEVELOPMENT INITIATIVES
6.1.4 ADVANCES IN DIAGNOSTIC TECHNOLOGIES
6.2 RESTRAINTS
6.2.1 LIMITED AWARENESS OF HEPATITIS DELTA VIRUS (HDV)
6.2.2 HIGH COST OF TREATMENT
6.3 OPPORTUNITIES
6.3.1 RISING INNOVATIVE DRUG DEVELOPMENT
6.3.2 INCREASING DEVELOPMENT OF COMBINATION THERAPIES
6.3.3 GROWING ADVANCEMENTS IN DIGITAL HEALTH SOLUTIONS
6.4 CHALLENGES
6.4.1 SIDE EFFECTS OF CURRENT TREATMENTS
6.4.2 SLOW REGULATORY APPROVALS
7 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
7.1 OVERVIEW
7.2 ACUTE HEPATITIS D
7.3 CHRONIC HEPATITIS D
8 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT
8.1 OVERVIEW
8.2 SURGERY (LIVER TRANSPLANT)
8.3 MEDICATION
8.3.1 APPROVED THERAPIES
8.3.1.1 PEGYLATED INTERFERON ALPHA
8.3.1.2 ENTRY INHIBITOR (BULEVIRTIDE)
8.3.2 EMERGING THERAPIES
9 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM
9.1 OVERVIEW
9.2 TABLET
9.3 CAPSULE
9.4 INJECTABLE
10 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE
10.1 OVERVIEW
10.2 BRANDED
10.3 GENERIC
11 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 CAPSULE
11.2.3 OTHERS
11.3 PARENTERAL
12 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER
12.1 OVERVIEW
12.2 FEMALE
12.3 MALE
13 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULTS
13.3 GERIATRIC
13.4 PEDIATRIC
14 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION
14.1 OVERVIEW
14.2 CONTAMINATED NEEDLES
14.3 EXPOSURE TO INFECTED BLOOD
14.4 BLOOD AND PLASMA PRODUCT TRANSFUSION
14.5 OTHERS
15 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CENTERS
15.4 HOME CARE SETTING
15.5 RESEARCH INSTITUTES & ACADEMIC CENTERS
15.6 AMBULATORY SURGICAL CENTERS
15.7 OTHERS
16 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.3.1 HOSPITAL PHARMACY
16.3.2 RETAIL PHARMACY
16.3.3 ONLINE PHARMACY
16.4 OTHERS
17 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
18 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 GILEAD SCIENCES, INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PIPELINE PRODUCT
20.1.5 RECENT DEVELOPMENTS
20.2 GENENTECH, INC.
20.2.1 COMPANY SNAPSHOT
20.2.2 PRODUCT PORTFOLIO
20.2.3 RECENT DEVELOPMENT
20.3 ALNYLAM PHARMACEUTICALS, INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 PIPELINE PRODUCT
20.3.4 RECENT DEVELOPMENTS
20.4 ASSEMBLY BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 PIPELINE PRODUCT
20.4.4 RECENT DEVELOPMENTS
20.5 EIGER BIOPHARMACEUTICALS
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 PIPELINE PRODUCT
20.5.6 RECENT DEVELOPMENT
20.6 GLOBEIMMUNE INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PIPELINE PRODUCT
20.6.3 RECENT DEVELOPMENT
20.7 HUAHUI HEALTH LTD.
20.7.1 COMPANY SNAPSHOT
20.7.2 PIPELINE PRODUCT
20.7.3 RECENT DEVELOPMENT
20.8 JOHNSON & JOHNSON SERVICES, INC.
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PIPELINE PRODUCT
20.8.4 RECENT DEVELOPMENT
20.9 PHARMAESSENTIA CORPORATION
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PIPELINE PRODUCT
20.9.4 RECENT DEVELOPMENT
20.1 REPLICOR
20.10.1 COMPANY SNAPSHOT
20.10.2 PIPELINE PRODUCT
20.10.3 RECENT DEVELOPMENTS
20.11 VIR BIOTECHNOLOGY, INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE ANALAYSIS
20.11.3 PRODUCT PIPELINE
20.11.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
TABLE 1 EMERGING NOVEL THERAPIES FOR HDV
TABLE 2 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 3 NORTH AMERICA ACUTE HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 4 NORTH AMERICA CHRONIC HEPATITIS D IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 6 NORTH AMERICA SURGERY (LIVER TRANSPLANT) IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 NORTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 8 NORTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 9 NORTH AMERICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 10 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 11 NORTH AMERICA TABLET IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 NORTH AMERICA CAPSULE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 NORTH AMERICA INJECTABLE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 15 NORTH AMERICA BRANDED IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 NORTH AMERICA GENERIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 NORTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 20 NORTH AMERICA PARENTERAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA FEMALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 23 NORTH AMERICA MALE IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 24 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 25 NORTH AMERICA ADULTS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 26 NORTH AMERICA GERIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 27 NORTH AMERICA PEDIATRIC IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 28 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 29 NORTH AMERICA CONTAMINATED NEEDLES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 30 NORTH AMERICA EXPOSURE TO INFECTED BLOOD IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 31 NORTH AMERICA BLOOD AND PLASMA PRODUCT TRANSFUSION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 32 NORTH AMERICA OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 33 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 34 NORTH AMERICA HOSPITALS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 35 NORTH AMERICA SPECIALTY CLINICS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 36 NORTH AMERICA HOME CARE SETTING IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 37 NORTH AMERICA RESEARCH INSTITUTES AND ACADEMIC CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 38 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 39 NORTH AMERICA OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 40 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 41 NORTH AMERICA DIRECT TENDER IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 42 NORTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 43 NORTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 44 NORTH AMERICA OTHERS IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 45 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 46 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)
TABLE 47 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 48 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 49 NORTH AMERICA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 50 NORTH AMERICA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 51 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 52 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 53 NORTH AMERICA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 54 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 55 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 56 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 57 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 58 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 59 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 60 NORTH AMERICA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 61 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 62 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 63 U.S. MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 64 U.S. APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 65 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 66 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 67 U.S. ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 68 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 69 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 70 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 71 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 72 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 73 U.S. HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 74 U.S. RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 75 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 76 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 77 CANADA MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 78 CANADA APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 79 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 80 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 81 CANADA ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 82 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 83 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 84 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 85 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 86 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 87 CANADA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 88 CANADA RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 89 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 90 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TREATMENT, 2022-2031 (USD THOUSAND)
TABLE 91 MEXICO MEDICATION IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 92 MEXICO APPROVED THERAPIES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 93 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)
TABLE 94 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 95 MEXICO ORAL IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
TABLE 96 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)
TABLE 97 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY AGE GROUP, 2022-2031 (USD THOUSAND)
TABLE 98 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY GENDER, 2022-2031 (USD THOUSAND)
TABLE 99 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TRANSMISSION, 2022-2031 (USD THOUSAND)
TABLE 100 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY END USER, 2022-2031 (USD THOUSAND)
TABLE 101 MEXICO HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 102 MEXICO RETAIL SALES IN HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE, 2022-2031 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SEGMENTATION
FIGURE 11 TWO SEGMENTS COMPRISE THE NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET, BY TYPE
FIGURE 12 GROWING PREVALENCE OF HEPATITIS IS DRIVING THE GROWTH OF THE NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET FROM 2024 TO 2031
FIGURE 13 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET IN 2024 AND 2031
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET
FIGURE 15 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2023
FIGURE 16 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 17 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 18 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 19 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2023
FIGURE 20 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, 2024-2031 (USD THOUSAND)
FIGURE 21 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 22 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 23 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2023
FIGURE 24 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)
FIGURE 25 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 26 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 27 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2023
FIGURE 28 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)
FIGURE 29 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 30 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 31 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 32 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 33 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 34 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER,2023
FIGURE 36 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, 2024-2031 (USD THOUSAND)
FIGURE 37 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 38 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2023
FIGURE 40 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, 2024-2031 (USD THOUSAND)
FIGURE 41 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 42 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 43 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2023
FIGURE 44 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, 2024-2031 (USD THOUSAND)
FIGURE 45 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, CAGR (2024-2031)
FIGURE 46 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY TRANSMISSION, LIFELINE CURVE
FIGURE 47 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2023
FIGURE 48 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 49 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, CAGR (2024-2031)
FIGURE 50 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY END USER, LIFELINE CURVE
FIGURE 51 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 52 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 53 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 54 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 55 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: SNAPSHOT (2023)
FIGURE 56 NORTH AMERICA HEPATITIS DELTA VIRUS (HDV) INFECTION MARKET: COMPANY SHARE 2023 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
